Gellad WF - Search Results

1

Accelerated Approval and Expensive Drugs - A Challenging Combination.

Gellad WF, Kesselheim AS. Gellad WF, et al. N Engl J Med. 2017 May 25;376(21):2001-2004. doi: 10.1056/NEJMp1700446. N Engl J Med. 2017. PMID: 28538133 No abstract available.

2

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.

San-Juan-Rodriguez A, Gellad WF, Good CB, Hernandez I. San-Juan-Rodriguez A, et al. Among authors: gellad wf. JAMA Netw Open. 2019 Dec 2;2(12):e1917379. doi: 10.1001/jamanetworkopen.2019.17379. JAMA Netw Open. 2019. PMID: 31834391 Free PMC article.

3

Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.

Cochran G, Cole ES, Warwick J, Donohue JM, Gordon AJ, Gellad WF, Bear T, Kelley D, DiDomenico E, Pringle J. Cochran G, et al. Among authors: gellad wf. Addict Sci Clin Pract. 2019 Aug 1;14(1):25. doi: 10.1186/s13722-019-0154-4. Addict Sci Clin Pract. 2019. PMID: 31366408 Free PMC article.

4

Impact of Star Rating Medication Adherence Measures on Adherence for Targeted and Nontargeted Medications.

Parekh N, Munshi KD, Hernandez I, Gellad WF, Henderson R, Shrank WH. Parekh N, et al. Among authors: gellad wf. Value Health. 2019 Nov;22(11):1266-1274. doi: 10.1016/j.jval.2019.06.009. Epub 2019 Aug 16. Value Health. 2019. PMID: 31708063

5

How the new medicare drug benefit could affect vulnerable populations.

Gellad WF, Huskamp HA, Phillips KA, Haas JS. Gellad WF, et al. Health Aff (Millwood). 2006 Jan-Feb;25(1):248-55. doi: 10.1377/hlthaff.25.1.248. Health Aff (Millwood). 2006. PMID: 16403761 Free PMC article.

6

Angiotensin receptor blockers on the formularies of Medicare drug plans.

Gellad WF, Huskamp HA, Phillips KA, Haas JS. Gellad WF, et al. J Gen Intern Med. 2007 Aug;22(8):1172-5. doi: 10.1007/s11606-007-0235-z. Epub 2007 May 15. J Gen Intern Med. 2007. PMID: 17503103 Free PMC article.

7

What if the federal government negotiated pharmaceutical prices for seniors? An estimate of national savings.

Gellad WF, Schneeweiss S, Brawarsky P, Lipsitz S, Haas JS. Gellad WF, et al. J Gen Intern Med. 2008 Sep;23(9):1435-40. doi: 10.1007/s11606-008-0689-7. Epub 2008 Jun 26. J Gen Intern Med. 2008. PMID: 18581187 Free PMC article.

8

Sources of regional variation in Medicare Part D drug spending.

Donohue JM, Morden NE, Gellad WF, Bynum JP, Zhou W, Hanlon JT, Skinner J. Donohue JM, et al. Among authors: gellad wf. N Engl J Med. 2012 Feb 9;366(6):530-8. doi: 10.1056/NEJMsa1104816. N Engl J Med. 2012. PMID: 22316446 Free PMC article.

9

Implications of new insurance coverage for access to care, cost-sharing, and reimbursement.

James AE 3rd, Gellad WF, Primack BA. James AE 3rd, et al. Among authors: gellad wf. JAMA. 2014 Jan 15;311(3):241-2. doi: 10.1001/jama.2013.283150. JAMA. 2014. PMID: 24337312 No abstract available.

10

Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011.

Gellad WF, Choi P, Mizah M, Good CB, Kesselheim AS. Gellad WF, et al. Am J Manag Care. 2014 Mar 1;20(3):e90-7. Am J Manag Care. 2014. PMID: 24773330

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results